idea-013 · narrative
A synthesis across this candidate's claims, dossier and decks — every statement here traces to something that already exists elsewhere in the knowledge base. A narrative never invents a fact, upgrades a tag, or recommends anything.
How to read this. This is a synthesis, not a new source of truth: every claim it cites carries the tag the candidate file gives it right now, copied not paraphrased, and every line quoted from a deck is quoted verbatim. See docs/narrative-spec.md.
This is a non-surgical, patient-self-inserted one-way valve seated at the stoma orifice, with a low-profile drainable external cap, proposed as an alternative to continuous-wear adhesive ostomy pouches for adults with a mature, uncomplicated (non-surgically-reconstructed) ileostomy. No prototype exists yet, and the regulatory story the candidate was generated under is the opposite of settled: the file's own predicate_or_analog field states plainly that no cleared predicate for this exact device shape was found, but a Verifier pass surfaced one anyway — a real Class II clearance the initial search missed [claim 12: refuted]. Only one of nine rubric factors carries any verified claim at all (Regulatory pathway, at 1/5), and only two claims in the whole file are verified — a narrow CFR classification covering the external cap component only [claim 2: verified], and a repo-state check that no ostomy/stoma dossier exists yet [claim 14: verified]. Everything about who would use it, who would pay for it, and whether the mechanism can be built at all is currently unconfirmed or unverified, and the candidate sits at status: queued-research.
The device sits next to an established, adjacent product category — adhesive ostomy pouching, covered by 21 CFR 876.5900 (Class I, exempt), whose product codes EXB, EZQ, and EZS were independently confirmed [claim 2: verified] — but the candidate itself states up front that no cleared 510(k) or De Novo predicate was identified for this exact device shape: a non-surgical, patient-removable indwelling valve for a standard ileostomy. That premise did not survive a Verifier pass. A search for "ileostomy valve" returned a real, cleared Class II device — the Waters Ileostomy Valve (K813585, Waters Instruments, Inc., cleared 1982-04-09, product code KNT, 21 CFR 876.5980) — directly contradicting the file's own framing [claim 12: refuted]. What that refutation settles and does not settle is carefully bounded in the file itself: it disproves "no search result exists," not "a usable predicate exists." K813585's actual Indications for Use cannot be read from any source this repo reaches (no 510(k) summary was ever posted for a filing that old), so whether it covers a standard, non-surgically-reconstructed ileostomy is still open, and the device predates 21 CFR 876.5030 (the continent-ileostomy-catheter classification) by seven months, leaving even which regulation currently governs unresolved. Two other candidate routes remain live: 876.5030 itself, confirmed to exist and to describe a Class I exempt, patient-inserted drainage device, but whose applicability to a standard (non-Kock-pouch) ileostomy the regulation text does not settle [claim 1: unconfirmed], and 876.5900, verified to cover the external cap/reservoir component specifically but not the valve-insert that is this device's actual novelty [claim 2: verified].
The competitive picture the candidate was generated against turned out to be similarly incomplete. Ampa Medical's InterPoc, an absorptive intraluminal device the Generator names as the nearest adjacent competitor and deliberately designs against, has no US FDA clearance found on independent check, consistent with the claim's own text [claim 3: unconfirmed]. But Coloplast's Heylo, a leak-notification accessory the original claim explicitly said carried no US clearance, does now have one — cleared 2025-10-06 under K252140, a date that predates this candidate's own 2026-08-30 generation date and was therefore findable at the time [claim 4: refuted].
On the demand side, the candidate's own design-rationale note flags, by name, that the whole design "rests on an unverified assumption that ostomy patients and their WOC (wound/ostomy/ continence) nurses would be willing to learn and perform daily self-insertion/removal of an intraluminal valve" — written into the file before any claim existed to carry it. The desirability deck formalized that exact assumption into three separate claims, all unverified: whether patients would accept daily self-insertion at all [claim 15: unverified], whether WOC nurses would train and support it [claim 16: unverified], and whether patients who tried it would prefer it to pouching beyond an initial trial [claim 17: unverified]. The nearest literature analog to the mechanism — a 1980 Silastic-tube-and-balloon indwelling valve studied in 14 patients, reporting "continuous and voluntary control ... without untoward local or systemic effects" — describes a different valve design in a different population (post-continent-ileostomy-surgery patients with a failed nipple valve, not this candidate's standard-ileostomy target) [claim 11: unconfirmed].
The size of the population this would even be sold to is itself unresolved: a figure of 725,000-1,000,000 Americans living with any ostomy (not ileostomy-specific), with roughly 100,000 new ostomy surgeries a year, cites no primary dataset [claim 5: unconfirmed]; a reported leakage-incidence range of 18%-76%, with over 81% of those experiencing leakage also reporting peristomal skin irritation, cites no PMID [claim 6: unconfirmed]. Nothing in the file names a price for this device, a HCPCS code for its own shape [claim 18: unverified], or a sustainable price point [claim 19: unverified] — the only billing category named at all is A4361-A4438, the category for the conventional pouching system this device would displace, and even that stays unconfirmed for a pure tooling reason: three local cache files this Verifier pass did not fetch [claim 7: unconfirmed]. The one market-size figure in the file, roughly $586.6 million, comes back unverifiable by the market connector's own design [claim 8: unconfirmed].
On the engineering side, no prototype exists, and the failure modes the Generator names — valve occlusion by particulate effluent, leakage past the valve seal, and skin/mucosal irritation at the retention collar — are its own unsourced reasoning, not evidence from any study [claim 13: unconfirmed], alongside two feasibility-deck write-backs asking whether the device could be manufactured and sterilized at a DMEPOS-compatible unit cost [claim 20: unverified] and whether a patient could self-insert and self-remove it safely without clinician supervision, without mucosal trauma, stenosis, or misplacement [claim 21: unverified]. A live, recently-issued, potentially load-bearing FTO patent — US 11,395,757 B2, "Continent ostomy valve and method of use" — was never actually read: both patent-connector calls failed for a missing API key, a tooling gap rather than a finding of clearance [claim 9: unconfirmed], and a body of adjacent leak-sensing patent art was named but tied to no specific patent number, so nothing there was checked either [claim 10: unconfirmed]. The one clean repo-state fact in the file is that no domain dossier exists yet for ostomy/stoma care [claim 14: verified] — there is accordingly no dossier for this narrative to cite as context.
knowledge-base/domains/ directory listing [claim 14: verified]
market connector reports
this class of claim unverifiable by design [claim 8: unconfirmed]
All three decks were built 2026-08-30, the same date as the candidate's own updated: stamp, and each is a first build — this candidate had no decks before this round.
The desirability deck turns on the same assumption the candidate's own design-rationale note already flagged by name before any claim existed to carry it — that ostomy patients and their WOC nurses would be willing to take on daily self-insertion and removal of an intraluminal valve. The deck formalized that exact assumption into a claim [claim 15: unverified].
"whether adults with a mature, standard ileostomy would be willing to learn and perform daily self-insertion and self-removal of an intraluminal stoma valve, in exchange for reduced pouch bulk and reduced adhesive-related skin exposure" — the load-bearing condition of the desirability deck (built 2026-08-30).
The viability deck does not turn on the regulatory question at all — it turns on revenue being unstated rather than merely unconfirmed: no HCPCS code names this device's own shape [claim 18: unverified], and no price figure for it exists anywhere in the file [claim 19: unverified].
"whether this device could be sold or billed at a price the DME/insurance payer or the patient would actually pay" — the load-bearing condition of the viability deck (built 2026-08-30).
The feasibility deck turns on the same finding that is this file's single most consequential Verifier result: which regulatory route actually governs, now that a real Class II predicate the frontmatter's own search missed has surfaced [claim 12: refuted], alongside the two still-unresolved Class I candidates [claim 1: unconfirmed] [claim 2: verified].
"which regulatory route actually governs this device — Class I exempt under 21 CFR 876.5030 or 876.5900 (partial coverage only), or Class II under 876.5980 or a De Novo grant" — the load-bearing condition of the feasibility deck (built 2026-08-30).
Where they don't agree: the three lenses stack rather than conflict. Feasibility's regulatory-route question has to resolve before viability's own capital-to-first-dollar question can even be scoped — the viability deck says so directly. Viability's revenue gap holds regardless of which regulatory path wins: even a fast, cheap regulatory path still produces no named way to get paid. Desirability's question sits upstream of both in a different sense — if patients will not accept daily self-insertion, neither a resolved regulatory answer nor a resolved price is ever tested against a real patient.
With the file's own predicate search now shown to have missed a real Class II clearance, and no price or billing code named anywhere for this device's own shape, does the willingness this candidate is actually built on — patients self-inserting and removing an intraluminal valve daily, and WOC nurses training them to do it — hold up once asked directly, or is this a mechanism argument against one adjacent competitor's absorptive device, built without ever checking the population it targets?